Activation of TxA2/PGH2 receptors and protein kinase C contribute to coronary dysfunction in superoxide treated rat hearts

J Mol Cell Cardiol. 2000 Jun;32(6):937-46. doi: 10.1006/jmcc.2000.1134.

Abstract

We have previously shown that superoxide anion (O2-) stimulates the release of vasoconstrictor prostanoids and induces a prolonged rise in coronary perfusion pressure (CPP) that persists even after removal of O2-. In this study, we tested the hypothesis that the increased CPP is mediated by activation of TxA2/ PGH2 (TP) receptors and protein kinase C (PKC)-dependent mechanisms. In Langendorff perfused rat hearts, O2- was applied for 15 min and then washed out over a period of 20 min. Application of O2- increased the release of vasoconstrictive (TxA2 and PGF2alpha) and decreased vasodilating (PGI2 and PGE2) prostanoids. Although indomethacin (10 microM), a cyclooxygenase inhibitor, attenuated the rise in CPP during O2- perfusion, the increase was not completely blocked. OKY 046Na (10 microM), a thromboxane synthase inhibitor, had no effect on O2--induced increases in CPP, whereas ONO 3708 (10 microM), a TP receptor antagonist, suppressed this effect. PKC activity was also elevated by more than 50% by O2- perfusion. CPP typically increased throughout the O2- wash-out. This post-O2- vasoconstriction was not inhibited by indomethacin, nitroglycerin or nitrendipine. In contrast, ONO 3708 (10 microM) and two PKC inhibitors, staurosporine (10 nM) and calphostin C (100 nM), completely blocked the rise in CPP, and even elicited vasodilation. PDBu enhanced the post-O2- vasoconstriction. We conclude that O2--induced coronary vasoconstriction is initially mediated by TP receptors, but activation of PKC sustains the response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / pharmacology
  • Animals
  • Calcium Channel Blockers / pharmacology
  • Cardiovascular Agents / pharmacology
  • Coronary Disease / enzymology
  • Coronary Disease / metabolism*
  • Dinoprost / pharmacology
  • Enzyme Inhibitors / pharmacology
  • In Vitro Techniques
  • Indomethacin / pharmacology
  • Male
  • Methacrylates / pharmacology
  • Naphthalenes / pharmacology
  • Perfusion
  • Prostaglandins / metabolism
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Prostaglandin / metabolism*
  • Receptors, Thromboxane / metabolism*
  • Receptors, Thromboxane A2, Prostaglandin H2
  • Staurosporine / pharmacology
  • Superoxides / metabolism*
  • Thromboxane A2 / analogs & derivatives
  • Thromboxane A2 / metabolism
  • Thromboxane A2 / pharmacology
  • Thromboxane-A Synthase / antagonists & inhibitors
  • Vasoconstrictor Agents / pharmacology

Substances

  • Calcium Channel Blockers
  • Cardiovascular Agents
  • Enzyme Inhibitors
  • Methacrylates
  • Naphthalenes
  • Prostaglandins
  • Receptors, Prostaglandin
  • Receptors, Thromboxane
  • Receptors, Thromboxane A2, Prostaglandin H2
  • Vasoconstrictor Agents
  • Superoxides
  • Thromboxane A2
  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • ONO 3708
  • Dinoprost
  • Protein Kinase C
  • Thromboxane-A Synthase
  • Staurosporine
  • calphostin C
  • ozagrel
  • Indomethacin